Breaking Finance News

Exelixis Inc (NDAQ:EXEL) target price raised to $32.00, issued a ratings update earlier today by RBC Capital Markets

Stating a potential upside of 0.17%, RBC Capital Markets bumped up the target of Exelixis Inc (NDAQ:EXEL) to $32.00

Previously on Tuesday September 12, 2017, Needham reported about Exelixis Inc (NDAQ:EXEL) bumped up the target price from $28.00 to $30.00. At the time, this indicated a possible upside of 0.11%.

Just yesterday Exelixis Inc (NDAQ:EXEL) traded 2.90% higher at $27.40. EXEL’s 50-day average is $27.05 and its two hundred day average is $23.36. With the last stock price close up 20.00% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 1,472,364 shares of the stock were exchanged, down from an average trading volume of 4,148,590

Recent Performance Chart

Exelixis Inc (NDAQ:EXEL)

Exelixis Inc has 52 week low of $10.04 and a 52 week high of $29.50 with a P/E ratio of 141.57 and has a market cap of $0.

Also covering Exelixis Inc's target, a total of 3 analysts have released a research note on Exelixis Inc. The 12-month price target is $7.00 with 3 firms rating the stock a strong buy, 1 brokerage rating the stock a buy, 1 brokerage rating the stock a hold, 0 brokers rating the stock a underperform, and finally zero analysts rating the company a sell.

General Company Details For Exelixis Inc (NDAQ:EXEL)

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *